Document Type
Poster
Publication Date
2019
Identifier/URL
39891083 (Pure)
Abstract
opical photodynamic therapy (PDT), or blue light therapy, isa procedure using a photosensitizing agent, or precursoragent 5-aminolevulinic acid (5-ALA), and is commonly usedto treat precancerous actinic keratosis. The 5-ALA is takenup by skin lesions through targeting cells with high turnoverthat are metabolically active (malignant proliferation) andconverted to the photoactive drug protoporphyrin IX.Following exposure to blue light, significant cell destructionoccurs which has been linked to the generation of reactiveoxygen species (1). Though PDT is effective, several studieshave suggested that this procedure results inimmunosuppression, which might limit the effectiveness ofthis therapy. Our group has demonstrated previously thatexperimental PDT of keratinocyte cell lines and murine skingenerates the lipid mediator Platelet-activating Factor (PAF).Moreover, we have found that PDT of wild-type mice resultsin immunosuppression, with PAF receptor knockout miceprotected from PDT-induced immunosuppression.
Repository Citation
Borchers, C. E.,
Rapp, C. M.,
Cates, E.,
Williams, A.,
& Travers, J. B.
(2019). Topical Photodynamic Therapy Induces Immunosuppression: Potential Role of Lipid Mediator Platelet-Activating Factor. .
https://corescholar.libraries.wright.edu/dermatology/26
